Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Fda save search
Viveve Announces FDA Approval to Conduct PURSUIT Trial for Improvement of Stress Urinary Incontinence
Published: 2020-07-07 (Crawled : 19:10) - ir.viveve.com
VIVE | $0.0002 59900.0% 1.4K
|
Health Technology
| Email alert
Add to watchlist
fda approval fda trial approval
BioPharma Services Inc., a Think Research Subsidiary, Achieves Another Successful FDA Inspection Result
Published: 2022-06-16 (Crawled : 15:00) - prnewswire.com
ARMV | $0.005 2214.82% 300
|
| Email alert
Add to watchlist
fda biopharma research services
Marizyme, Inc. Announces FDA Clearance for Flagship Product, DuraGraft™
Published: 2023-10-06 (Crawled : 13:00) - globenewswire.com
MRZM | $0.095 1031.22% 2.2K
|
Information
|
| O: 3.37%
H: 76.09%
C: 43.48%
fda clearance
Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of OLPRUVA™ for Patients with Urea Cycle Disorders
Published: 2022-12-27 (Crawled : 14:00) - globenewswire.com
RLFTF | $1.43 11.45% 3.8K
|
n/a
|
| O: 3.33%
H: 12.26%
C: 8.06%
RLFTY | $1.4006 733.33% 100
|
n/a
|
| O: 2.37%
H: 0.0%
C: 0.0%
ACER | $0.9 -3.61% 420K
|
Health Technology
|
| O: -3.23%
H: 0.28%
C: -31.11%
urea fda approval therapeutics
Acer Therapeutics and Relief Therapeutics Announce Update on U.S. FDA Review of New Drug Application (NDA) for ACER-001
Published: 2022-06-21 (Crawled : 16:00) - biospace.com/
RLFTF | $1.43 11.45% 3.8K
|
n/a
|
| O: -21.33%
H: 27.12%
C: 14.41%
RLFTY | $1.4006 733.33% 100
|
n/a
|
| O: -15.91%
H: 8.65%
C: 8.65%
ACER | $0.9 -3.61% 420K
|
Health Technology
|
| O: -10.23%
H: 0.0%
C: 0.0%
acer-001 fda drug application therapeutics review update
Relief Reports that its U.S. Collaboration Partner has Announced that the FDA has Declined Emergency Use Authorization for Aviptadil for a Subgroup of Patients with Critical COVID-19 at Immediate Risk
Published: 2022-07-04 (Crawled : 10:00) - biospace.com/
RLFTF | $1.43 11.45% 3.8K
|
n/a
| Email alert
Add to watchlist
RLFTY | $1.4006 733.33% 100
|
n/a
| Email alert
Add to watchlist
NRXP 2 d | $3.08 1.99% 1.95% 230K
|
Manufacturing
| Email alert
Add to watchlist
covid-19 fda risk collaboration aviptadil authorization emergency use authorization
Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ACER-001 for Treatment of UCDsPrescription Drug User Fee Act (PDUFA) target action date set for January 15, 2023
Published: 2022-07-28 (Crawled : 15:20) - biospace.com/
RLFTF | $1.43 11.45% 3.8K
|
n/a
|
| O: 3.08%
H: 0.0%
C: -6.79%
ACER | $0.9 -3.61% 420K
|
Health Technology
|
| O: 0.7%
H: 4.86%
C: -1.39%
acer-001 treatment fda drug set resubmission therapeutics review
Relief Therapeutics Announces that its Collaboration Partner has Resubmitted the ACER-001 (Sodium Phenylbutyrate) New Drug Application (NDA) to the FDA for the Treatment of Urea Cycle Disorders (UCDs)
Published: 2022-07-18 (Crawled : 09:00) - biospace.com/
RLFTF | $1.43 11.45% 3.8K
|
n/a
|
| O: 4.11%
H: 0.0%
C: -10.53%
acer-001 urea treatment fda drug collaboration application therapeutics
Relief Reports US Collab. Partner Announces Submission to FDA seeking EUA for Aviptadil for Pts at Immediate Risk of Death from COVID-19 Despite Treatment w/Remdesivir, Other Approved Therapies
Published: 2022-01-06 (Crawled : 10:00) - biospace.com/
RLFTF | $1.43 11.45% 3.8K
|
n/a
|
| O: 19.47%
H: 3.85%
C: -11.85%
RLFTY | $1.4006 733.33% 100
|
n/a
|
| O: 2.87%
H: 0.0%
C: 0.0%
NRXP 2 d | $3.08 1.99% 1.95% 230K
|
Manufacturing
|
| O: -3.39%
H: 6.19%
C: 3.92%
covid-19 treatment fda aviptadil risk covid media submission
FDA Guidance Clarifies Approach to Decentralized Clinical Trials – Ropes & Gray LLP
Published: 2023-05-05 (Crawled : 16:00) - spacfeed.com
ESAB | $106.02 0.22% 0.0% 190K
|
n/a
|
| O: 0.7%
H: 2.81%
C: 2.47%
MODD 4 | $1.66 -2.35% -2.41% 22K
|
|
| O: -1.13%
H: 1.84%
C: 1.14%
fda trials
Bioxytran Announces FDA Clearance of its IND Application for ProLectin-M in Clinical Trials
Published: 2023-08-24 (Crawled : 13:00) - globenewswire.com
BIXT A | $0.1285 490.75% 32K
|
Professional, Scientific, and T...
|
| O: 15.56%
H: 0.5%
C: -4.77%
fda clearance trials application
Bellicum Reports FDA Lifted Clinical Hold on BPX-601 Phase 1/2 Clinical Trial
Published: 2021-01-28 (Crawled : 22:01) - globenewswire.com
BLCM | $0.0748 381.28% 6.1K
|
Health Technology
|
| O: 26.04%
H: 22.52%
C: -3.93%
fda trial phase 3 phase 1 phase 2 clinical hold
Mallinckrodt Announces Submission of 510(k) to the U.S. FDA for Inhaled Nitric Oxide Delivery System
Published: 2022-09-28 (Crawled : 11:00) - prnewswire.com
MNKPF | $17.25
|
n/a
|
| O: 0.0%
H: 0.0%
C: 0.0%
fda system submission
Mallinckrodt Receives U.S. FDA Approval for Terlivaz® (terlipressin) for injection for the Treatment of Hepatorenal Syndrome (HRS)
Published: 2022-09-15 (Crawled : 03:00) - prnewswire.com
MNKPF | $17.25
|
n/a
|
| O: 10.71%
H: 16.13%
C: 15.81%
terlivaz treatment fda approval injection
Mallinckrodt Announces Resubmission of Terlipressin to the FDA for the Treatment of Hepatorenal Syndrome
Published: 2022-06-13 (Crawled : 12:00) - prnewswire.com
MNKKQ | $0.02
|
Manufacturing
|
| O: 0.33%
H: 9.48%
C: -75.33%
treatment fda resubmission
Mallinckrodt Receives U.S. FDA Approval for Lisdexamfetamine Dimesylate Capsules and Launches Product Used to Treat Attention-Deficit/Hyperactivity Disorder (ADHD)
Published: 2023-08-31 (Crawled : 19:00) - biospace.com/
MNKPF | $17.25
|
n/a
| Email alert
Add to watchlist
MNK | $0.3402 -0.06% 540K
|
n/a
| Email alert
Add to watchlist
MNKKQ | $0.02
|
Manufacturing
| Email alert
Add to watchlist
fda approval treat
Mallinckrodt Announces FDA Clearance of the INOmax® EVOLVE™ DS Delivery System and Approval of the INOmax® (nitric oxide) Mini-Cylinder
Published: 2023-12-07 (Crawled : 23:00) - prnewswire.com
MNKPF | $17.25
|
n/a
| Email alert
Add to watchlist
MNK | $0.3402 -0.06% 540K
|
n/a
| Email alert
Add to watchlist
MNKTQ | $0.12 -66.67% 39K
|
Manufacturing
| Email alert
Add to watchlist
MNKKQ | $0.02
|
Manufacturing
| Email alert
Add to watchlist
inomax fda approval clearance system
Mallinckrodt Announces U.S. FDA Approval of Supplemental New Drug Application for Acthar® Gel (repository corticotropin injection) Single-Dose Pre-filled SelfJect™ Injector
Published: 2024-03-01 (Crawled : 15:00) - biospace.com/
MNKKQ | $0.02
|
Manufacturing
| Email alert
Add to watchlist
MNK | $0.3402 -0.06% 540K
|
n/a
| Email alert
Add to watchlist
MNKPF | $17.25
|
n/a
| Email alert
Add to watchlist
MNKTQ | $0.12 -66.67% 39K
|
Manufacturing
| Email alert
Add to watchlist
acthar fda drug approval gel application
Seres Therapeutics Announces FDA Acceptance of Biologics License Application for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection for Priority Review
Published: 2022-10-26 (Crawled : 12:00) - biospace.com/
IMUN | $0.093 214.52% 1.8K
|
Manufacturing
|
| O: 2.22%
H: 8.7%
C: 8.7%
MCRB | $0.5671 -2.93% -3.02% 3.7M
|
Health Technology
|
| O: 1.39%
H: 16.24%
C: 12.65%
ser-109 fda application license therapeutics review infection
Seres Therapeutics and Nestlé Health Science Announce FDA Approval of VOWSTTM (fecal microbiota spores, live-brpk) for Prevention of Recurrence of C. difficile Infection in Adults Following Antibacterial Treatment for Recurrent CDI
Published: 2023-04-27 (Crawled : 08:00) - biospace.com/
MCRB | $0.5671 -2.93% -3.02% 3.7M
|
Health Technology
|
| O: 3.12%
H: 0.76%
C: -19.39%
fda antibacterial health approval infection treatment therapeutics
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.